Brain

Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a “Buy” Recommendation

Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation…

1 year ago

Healthy Directions Partners with Dr. Kulreet Chaudhary to Combine the Tradition Of Ayurvedic Practice with Modern-Day Science

Dr. Kulreet Chaudhary Partners with Healthy Directions Neurologist and Ayurvedic practitioner, Dr. Kulreet Chaudhary has developed Prajna Ayurveda herbals with…

1 year ago

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for…

1 year ago

High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem

-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE…

1 year ago

Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

-- Full results from ELPIS I trial published in European Heart Journal Open –         -- First patient to be randomized…

1 year ago

Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks…

1 year ago

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,…

1 year ago

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal…

1 year ago

Cerevance Announces Upcoming Presentation at the Alzheimer’s Research UK Conference 2023 

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel…

1 year ago